SAN FRANCISCO--(BUSINESS WIRE)--Herophilus, a leading biotechnology company with the mission to discover neurotherapeutics to cure complex brain diseases, today announced that Genentech, a member of the Roche Group, has acquired its proprietary high-throughput human organoid-based drug discovery platform comprising the Orchard™, Orchestra™, and OrCA™ technologies.

旧金山-（商业线）-领先的生物技术公司Herophilus，致力于发现治疗复杂脑部疾病的神经治疗药物，今天宣布，罗氏集团成员Genentech已收购其专有的高通量人类基于类器官的药物发现平台，包括果园™, 乐队™, 和OrCA™ 技术。

Herophilus will continue to advance its own ongoing neurotherapeutic research programs..

Herophilus将继续推进自己正在进行的神经治疗研究项目。。

“Since our founding in 2017, Herophilus’s vision has been to leverage the parallel revolutions in human complex in vitro brain models, scaled laboratory automation, and scientific machine learning to break the decades-long logjam in neuroscientific drug discovery. We are thrilled that Genentech will combine Herophilus’ platform with its exceptional drug development ability and experience to accelerate this vision,” said Saul Kato, CEO and Co-founder of Herophilus..

“自2017年成立以来，Herophilus的愿景一直是利用人类复杂的体外大脑模型，规模化的实验室自动化和科学机器学习的平行革命，打破长达数十年的神经科学药物发现日志。我们很高兴Genentech将把Herophilus的平台与其卓越的药物开发能力和经验结合起来加速这一愿景，”Herophilus首席执行官兼联合创始人Saul Kato说。。

This transaction provides the Genentech and Roche R&D units with these three components of Herophilus’ discovery platform:

该交易为Genentech和Roche R＆D units提供了Herophilus发现平台的这三个组件：

Orchestra: Comprehensive hybrid-cloud enterprise-scale software system for instrument and automation control, experiment tracking, provenant data and metadata management, high-performance microscopy imaging and video data visualization and exploration, data annotation and rapid machine learning pipeline development.

Orchestra：用于仪器和自动化控制，实验跟踪，出处数据和元数据管理，高性能显微成像和视频数据可视化和探索，数据注释和快速机器学习管道开发的综合云企业规模软件系统。

OrCA: Modular Organoid Culture and Assay scaled experimental system, comprising five function-specific workcells and a library of optimized biology protocols for low-variability, tuned organoid culture and high-content, high-throughput phenotypic assays

OrCA：模块化类器官培养和测定规模的实验系统，包括五个功能特异性工作细胞和一个优化的生物学方案库，用于低变异性，调整的类器官培养和高含量，高通量表型分析

Orchard: Protocol library for high-quality reprogramming and genetic engineering of organoid-optimized stem cell lines and access to a diversified neurological disease patient stem cell biobank

Orchard：用于器官优化干细胞系的高质量重编程和基因工程的方案库，并获得多样化的神经疾病患者干细胞生物库

Doug Flanzer, CTO, added “We built the Herophilus Discovery Engine from the ground up to power a new model for tech-enabled scientific discovery. This modern discovery paradigm is based on the generation of large-scale, complex experimental datasets and the application of machine learning / artificial intelligence to unravel complex disease etiology, discover new targets, illuminate mechanisms of action, and develop disease-modifying therapeutic interventions.

道格·弗兰泽，首席技术官，补充“我们从头开始构建了Herophilus发现引擎，为技术支持的科学发现提供了新模型。这种现代发现范式基于大规模，复杂的实验数据集的生成以及机器学习/人工智能的应用解开复杂的疾病病因，发现新目标，阐明作用机制，发展di修改治疗干预措施。

Such a complex data-driven approach needs an enterprise-strength full-lifecycle scientific data management system, which simply did not exist when we started Herophilus. I’m excited to see the dream realized.”.

这种复杂的数据驱动方法需要一个企业实力全生命周期科学数据管理系统，当我们启动Herophilus时，这个系统根本不存在。我很高兴看到梦想实现了。”。

About Herophilus

关于希罗菲利斯

Herophilus is a San Francisco-based neurotherapeutics company focused on curing complex brain diseases. The company combines brain organoid science, systems neuroscience, robotic automation, and advanced machine learning techniques to scale the ability to discover novel drugs for complex neurological and psychiatric diseases.

Herophilus是一家以旧金山为基地的神经治疗公司，专注于治疗复杂的脑部疾病。该公司结合了脑器官科学，系统神经科学，机器人自动化和先进的机器学习技术，以扩展发现复杂神经和精神疾病新药的能力。

The company has pioneered the use of multi-modal phenotypic screening in complex in vitro models to discover characterizations of diseases never before achievable. These deep phenotypes are exploited to identify novel therapeutic targets and drug treatments for disorders for which traditional discovery techniques have proved least successful, including neurodevelopmental, psychiatric and neurodegenerative diseases.

该公司率先在复杂的体外模型中使用多模式表型筛选来发现从未可实现的疾病特征。利用这些深层表型来鉴定传统发现技术证明最不成功的疾病的新型治疗靶标和药物治疗，包括神经发育，精神病和神经退行性疾病。

To learn more, visit www.herophilus.com..

To learn more, visit www.herophilus.com..